IUPHAR Lifetime Achievement Award and General Assembly Meeting Minutes

at the 19th World Congress of Basic and Clinical Pharmacology

5 July at 5:30pm in the Clyde Auditorium

Invited Attendees:

Brad Urquhart
Andrea Huwiler
Clive Page
Rachel Lambert-Forsyth
Baiba Svalbe
Priyadarshani Galappatthy
Wan-Wan Lin
Wen Chang Chang
Nada Salem
Christiaan Brink
Hafiza Parkar
Makhotso Lekhooa
Gordana Dragović Lukić
Saša Vukmirović
Saša Vasilev
Dragana Srebro
Dave Jackson
Mike Jarvis
Maribel Lucena
Horia Paunescu
Marco Pistis
Giuseppe Cirino
Maria rosaria Bucci
Silvana Gaetani
Piotr Ruszkowski
Azizah Ugusman
Jana Lass
Maria José de Oliveira
Diógenes Nogueira
Katerina (Ekaterini) Tiligada
Kevin Pfleger
Carl Kirkpatrick
Alastair Stewart
Gavin Dawe
Lars Gustafsson
Marja-Liisa Dahl
Merve Denizalti
Sinem Ezgi Gulmez
Mabel Catalan
Peter Ferdinandy
Zsuzsanna Helyes
John Rudd
Timo Myöhänen
Merja Voutilainen
Weverton Castro
InKyeom Kim
1. **General organization**: The meeting was very well attended, quorate and followed by a reception. The slides

2. **Presentation of the Lifetime Achievement Award**: Dr. Cascorbi presented the IUPHAR Lifetime Achievement Award to Dr. William Catterall along with a short introduction and biography of Dr. Catterall’s many accomplishments and achievements.

3. **Dr. Catterall’s Lecture**: Dr. Catterall thanked the IUPHAR Executive Committee for the honor of being named the recipient of the IUPHAR Lifetime Achievement Award. He then gave a twenty-minute lecture on ‘Voltage Gated Sodium and Calcium Channels at Atomic Resolution: Structure, Function, and Pharmacology’.

4. **Welcome of the President**: facilitated by Dr. Ingolf Cascorbi
   a. Members of the Executive Committee introduced themselves.
   b. A moment of silence for Prof. Sam Enna, past president of IUPHAR and secretary general for eight years, who passed away in June was respected.

5. **Development of Governance**: facilitated by Dr. Ingolf Cascorbi
   a. The strategic plan of IUPHAR was reviewed.
   b. The Executive Committee structure was briefly explained.
   c. The terms of office were outlined and explained.
   d. The allocated activities of each Section and Committee were explained.
   e. IUPHAR’s partnerships with larger medical associations were explained.
6. **Report of IUPHAR Activities**: facilitated by Dr. Michael Spedding
   a. Global Deaths High SDI vs. Global Deaths Low SDI were compared.
   b. Alliances with scientific societies and broader agreements were outlined.
   c. Overarching activities of IUPHAR, such as The Kyoto Congress and the World Congress of Pharmacology on Natura Products, were explained.
   d. IUPHAR’s response to Covid-19 was reviewed.
   e. IUPHAR issues and activities for audience members to participate in were outlined.

7. **Section Reports**: facilitated by Section Chairs
   a. Dr. Samer summarized the activities of the Clinical and Translational Section including: publishing two position papers, launching World Smart Medication Day, collaborations with pharmacology visibility, collaborations with agencies interested in the rational use of drugs, promoting meetings and workshops in clinical pharmacology around the world, improving and harmonizing the use of rational use of medicines at the graduate and undergraduate level, and outlining current and future tasks and projects.
   b. Drs. Ahluwalia, Maffia and Gyires summarized the activities of the Basic and Translational Section including: updating and harmonizing the website, reviewing and updating the structure of the Committees that fall under the Section and creating three new Committees. Dr. Maffia provided updates on activity of the Immunopharmacology Committee. Dr. Schini-Kerth provided updates on the activity of the Pharmacology of Natural Products Committee. Dr. Gyires provided updates on the Gastrointestinal Pharmacology Committee. Dr. Ahluwalia called for applications for Chairs for the new Cardiovascular and Cancer Committees.
c. Dr. Alexander summarized the activities of the NC-IUPHAR Section including: their twice-yearly meetings, work with actionable genes, pharmacological reviews, the Concise GuideToPharmacology, and publications in the British Journal of Pharmacology.

d. Dr. Guilding summarized the activities of the Education Section including: the Pharmacology Education Project, the Core Concepts of Pharmacology Projects, and the Pharmacology Education meetings and networking events. Dr. David Lewis spoke for a moment on the integrative and organ systems pharmacology initiative (IOSP).

e. Dr. Minervini summarized the aims of the Early Career Research Section.

f. Dr. Beata Sperlágh summarized the activities of the Governance Section including reviewing and editing IUPHAR’s Operating Manual.

8. Approval of the Executive Committee’s Action and Discharge from its Responsibilities: Dr. Somogyi moved a motion to approve the Executive Committee’s actions (listed in 5-7) and discharge from its responsibilities. There were no objections.

9. Treasurer’s Report: facilitated by Dr. Pierre Marquet

   a. IUPHAR’s operations income over the course of five years was reviewed and explained.

   b. IUPHAR’s operations expenses over the course of five years were reviewed and explained.

   c. IUPHAR’s assets over the course of five years were reviewed and explained.

   d. IUPHAR’s provisional budget (expenses) for 2023 was reviewed and explained.

   e. IUPHAR’s provisional budget (income and balance sheet) for 2023 was reviewed and explained.
f. Dr. Urs Rügg asked why there was no meetings income from WCP2023. Rachel Lambert-Forsyth, CEO BPS responded that there will be no contribution to IUPHAR’s income due to a negative financial balance of WCP2023 because of lower delegate attendance as expected. Possible reasons are various global obstacles upfront the congress like the economic impact of the pandemic, and difficulties with travel visas. Due to the contract, IUPHAR is not responsible for any loss from WCP2023.

g. Dr. Marquet explained that the economy is improving, and he expects a positive balance in the near future.

10. Approval of Annual Financial Statements and Discharge from the Treasurer’s Responsibilities: Dr. Lewis moved a motion to approve the annual financial statements and discharge from the Treasurer’s responsibilities. There were no objections.

11. IUPHAR Plan to 2026: facilitated by Dr. Levi-Schaffer
   a. Aims for IUPHAR such as furthering scientific research, development, and knowledge of pharmacology and harmonizing pharmacology were reviewed. Specific actions for how to accomplish those aims were also reviewed.

12. Call for Future WCP: facilitated by Dr. Michael Spedding
   a. The call for 2030 bids for WCP was announced by Dr. Spedding. The decision will be made at the 2026 General Assembly.

13. Presentation of WCP2026: facilitated by Dr. Carl Kirkpatrick
   a. An announcement regarding WCP2026 in Melbourne Australia was made. It was announced that the event will be held at the Melbourne Convention Exhibition Centre. It was also communicated that the Centre addresses all accommodation needs. The Program of the event was reviewed as well.

14. General Discussion: The following comments were made:
   a. There were no comments.
The General Assembly ended at 7:30 pm, and the attendees were encouraged to head to the Castle Suite at the Crowne Plaza Hotel for the General Assembly Reception.